HDAC inhibitors (HDACi) are a class of compounds that inhibit the enzymatic activity of HDACs. They have shown promise as therapeutic agents in the treatment of various diseases, particularly cancer. By inhibiting HDACs, these compounds can induce cell cycle arrest, promote apoptosis, and enhance the expression of tumor suppressor genes. Some HDAC inhibitors, such as vorinostat and romidepsin, have been approved by the FDA for the treatment of certain types of lymphoma.
